MG
MRNA icon

Mather Group’s Moderna MRNA Stock Holding History

Mather Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$533K Sell
7,604
-41
-0.5% -$2.12K ﹤0.01% 521
2026
Q1 		$388K Buy
7,645
+551
+8% +$25.7K ﹤0.01% 557
2025
Q4 		$209K Sell
7,094
-3,402
-32% -$92.4K ﹤0.01% 616
2025
Q3 		$271K Sell
10,496
-418
-4% -$11.7K ﹤0.01% 541
2025
Q2 		$301K Buy
10,914
+7,035
+181% +$185K ﹤0.01% 494
2025
Q1 		$110K Buy
3,879
+3,201
+472% +$114K ﹤0.01% 724
2024
Q4 		$28.2K Sell
678
-603
-47% -$28.8K ﹤0.01% 992
2024
Q3 		$85.6K Buy
1,281
+262
+26% +$24.1K ﹤0.01% 770
2024
Q2 		$109K Buy
1,019
+443
+77% +$56.1K ﹤0.01% 786
2024
Q1 		$57.3K Buy
+576
New +$58.1K ﹤0.01% 843
2023
Q1 		– Sell
-6,599
Closed -$1.19M – 516
2022
Q4 		$1.19M Sell
6,599
-601
-8% -$98.3K 0.02% 186
2022
Q3 		$851K Sell
7,200
-531
-7% -$80.6K 0.02% 217
2022
Q2 		$1.1M Buy
7,731
+1,836
+31% +$262K 0.03% 168
2022
Q1 		$1.01M Buy
+5,895
New +$992K 0.02% 169

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Mather Group's MRNA Position: Q2 2026 in Review

Mather Group reduced its Moderna (MRNA) stake by 0.54% in Q2 2026, selling an estimated $2.12K and leaving 7,604 shares worth $533K. The position accounts for ﹤0.01% of the portfolio, ranked #521.

Mather Group first reported a position in MRNA in Q1 2022 and has held it in 14 quarters since. The position peaked at $1.19M in Q4 2022. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Mather Group held 7,604 shares of Moderna worth $533K as of Q2 2026.
  • Mather Group sold 41 Moderna shares in Q2 2026, an estimated $2.12K.
  • Moderna made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #521 holding.
  • Mather Group first reported a position in Moderna in Q1 2022 and has held it in 14 quarters since.
  • Mather Group's Moderna position peaked at $1.19M in Q4 2022.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.